ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,039.16
      -2.09%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      73.885
      -0.30%
      Bitcoin
      95,783.34
      -0.51%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Phathom Pharmaceuticals Inc (PHAT) Quote

      Phathom Pharmaceuticals Inc

      Phathom Pharmaceuticals Inc (PHAT)

      NASDAQ
      5.67
      0.13
      (2.35%)
      Closed February 24 4:00PM
      Delayed by 15 minutes
      5.77
      0.10
      (1.76%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      5.77
      Bid
      5.67
      Ask
      5.73
      Volume
      723,073
      5.53 Day's Range 5.755
      5.21 52 Week Range 19.675
      Market Cap
      394.537M
      Previous Close
      5.54
      Open
      5.59
      Last Trade
      30
      @
      5.67
      Last Trade Time
      Financial Volume
      $ 4,058,239
      VWAP
      5.6125
      Average Volume (3m)
      983,304
      Shares Outstanding
      68,377,379
      Dividend Yield
      -
      PE Ratio
      -1.93
      Earnings Per Share (EPS)
      -2.95
      Revenue
      682k
      Net Profit
      -201.59M

      About Phathom Pharmaceuticals Inc

      Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that ... Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.phathompharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Phathom Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHAT. The last closing price for Phathom Pharmaceuticals was $5.54. Over the last year, Phathom Pharmaceuticals shares have traded in a share price range of $ 5.21 to $ 19.675.

      Phathom Pharmaceuticals currently has 68,377,379 shares outstanding. The market capitalization of Phathom Pharmaceuticals is $378.81 million. Phathom Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.93.

      Ask ADVFN Intelligence (AI)

      PHAT Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 23 2025
      PHAT (2.35%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 20 2024
      PHAT (2.35%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 16 2024
      PHAT (2.35%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 11 2024
      PHAT (2.35%)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors
      Edgar (US Regulatory)
      November 12 2024
      PHAT (2.35%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 07 2024
      PHAT (2.35%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 07 2024
      PHAT (2.35%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.285-4.70685383986.0556.215.4959532395.71464315CS
      4-1.38-19.30069930077.157.255.2110275995.95626213CS
      12-3.13-35.16853932588.99.795.219833047.10813742CS
      26-7.12-55.23661753312.8919.6755.21116287911.82648046CS
      52-4.16-41.89325276949.9319.6755.2193815311.36910779CS
      156-12.28-68.033240997218.0519.6755.2155134110.66925241CS
      260-37.24-86.58451522943.0164.545.2136967713.18052055CS

      PHAT - Frequently Asked Questions (FAQ)

      What is the current Phathom Pharmaceuticals share price?
      The current share price of Phathom Pharmaceuticals is $ 5.77
      How many Phathom Pharmaceuticals shares are in issue?
      Phathom Pharmaceuticals has 68,377,379 shares in issue
      What is the market cap of Phathom Pharmaceuticals?
      The market capitalisation of Phathom Pharmaceuticals is USD 378.81M
      What is the 1 year trading range for Phathom Pharmaceuticals share price?
      Phathom Pharmaceuticals has traded in the range of $ 5.21 to $ 19.675 during the past year
      What is the PE ratio of Phathom Pharmaceuticals?
      The price to earnings ratio of Phathom Pharmaceuticals is -1.93
      What is the cash to sales ratio of Phathom Pharmaceuticals?
      The cash to sales ratio of Phathom Pharmaceuticals is 569
      What is the reporting currency for Phathom Pharmaceuticals?
      Phathom Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Phathom Pharmaceuticals?
      The latest annual turnover of Phathom Pharmaceuticals is USD 682k
      What is the latest annual profit for Phathom Pharmaceuticals?
      The latest annual profit of Phathom Pharmaceuticals is USD -201.59M
      What is the registered address of Phathom Pharmaceuticals?
      The registered address for Phathom Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
      What is the Phathom Pharmaceuticals website address?
      The website address for Phathom Pharmaceuticals is www.phathompharma.com
      Which industry sector does Phathom Pharmaceuticals operate in?
      Phathom Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      BOXLBoxlight Corporation
      $ 3.1099
      (51.70%)
      		1.84M
      GDEVGDEV Inc
      $ 20.90
      (46.56%)
      		264.44k
      IVVDInvivyd Inc
      $ 1.7501
      (44.64%)
      		37.75M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      DOYUDouYu International Holdings Ltd
      $ 7.19
      (-55.31%)
      		1.28M
      MNDRMobile health Network Solutions
      $ 0.5048
      (-46.29%)
      		18.61M
      BLUEbluebird bio Inc
      $ 4.09
      (-41.90%)
      		5.44M
      FLDFold Holdings Inc
      $ 6.95
      (-37.39%)
      		488.54k
      GCLGCL Global Holdings Ltd
      $ 3.83
      (-31.48%)
      		635.26k
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      ADTXAditxt Inc
      $ 0.0922
      (-22.39%)
      		278.25M
      NVDANVIDIA Corporation
      $ 134.43
      (-4.05%)
      		228.14M
      HOLOMicroCloud Hologram Inc
      $ 1.565
      (31.51%)
      		190.81M

      PHAT Discussion

      View Posts
      rolvram rolvram 3 months ago
      Blackrock keeps accumulating
      https://stockzoa.com/ticker/phat/ownership/blackrock/#google_vignette
      👍️0
      Monksdream Monksdream 5 months ago
      PHAT new 52=high

      👍️0
      MiamiGent MiamiGent 7 months ago
      PHAT Nice! Account increased 11%! Was stacked.
      👍️0
      MiamiGent MiamiGent 7 months ago
      PHAT 28.5% Revenue beat!
      👍️0
      MiamiGent MiamiGent 7 months ago
      PHAT Still in.
      👍️0
      FALCON1 FALCON1 7 months ago
      https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

      https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
      👍️0
      MiamiGent MiamiGent 7 months ago
      HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
      BENZINGA

      Jul-19-2024 6:41 a.m. ET

      HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (PHAT) with a Buy and maintains $28 price target.
      👍️0
      MiamiGent MiamiGent 7 months ago
      PHAT I'm hanging in!
      👍️0
      MiamiGent MiamiGent 7 months ago
      BRIEF-Phathom Pharmaceuticals Announces FDA Approval Of Voquezna® (Vonoprazan) Tablets For The Relief Of Heartburn Associated With Non-Erosive Gerd In Adults
      REUTERS

      Jul-18-2024 8:41 a.m. ET

      July 18 (Reuters) - Phathom Pharmaceuticals Inc (PHAT) :

      * PHATHOM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VOQUEZNA® (VONOPRAZAN) TABLETS FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GERD IN ADULTS

      * PHATHOM PHARMACEUTICALS INC (PHAT): VOQUEZNA MET ITS PRIMARY ENDPOINT IN ITS PHASE 3 PIVOTAL TRIAL Source text for Eikon: Further company coverage:
      👍️0
      MiamiGent MiamiGent 7 months ago
      $PHAT FLE.
      👍️0
      MiamiGent MiamiGent 7 months ago
      PHAT In @ 12.60's
      👍️0
      Monksdream Monksdream 10 months ago
      PHAT under $10
      👍️0
      Monksdream Monksdream 12 months ago
      PHAT 10Q due March 7
      👍️0

      Your Recent History

      NASDAQ
      PHAT
      Phathom Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads